Experimental study reveals gasdermin D pores admit impermeable caspase inhibitors into pyroptotic cells, highlighting a strategy to achieve cell-state drug selectivity.
Caspase inhibitors have repeatedly entered clinical trials but have not reached clinical practice due to toxicity and limited efficacy. Groborz and colleagues now show that gasdermin D pores admit otherwise membrane-impermeable inhibitors into pyroptotic cells, turning poor permeability into a mechanism of cell-state selectivity.
No takes yet. Share an insight, caveat, or question.
Ivano Amelio (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: